MS-209 Schering.
MS-209, a quinolone-derived sphingomyelin synthase inhibitor that blocks P-glycoprotein and multidrug resistance-associated protein-1, is under development by Schering for the potential treatment of multidrug resistant tumors. By March 2003, phase II trials in breast cancer and non-small-cell lung cancer had been initiated.
Robert
Jacques
J
Institut Bergonié and Université Victor Segalen, 229 Cours de l'Argonne, 33076 Bordeaux Cedex, France. robert@bergonie.org
D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D015507:Drugs, Investigational / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D011804:Quinolines / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D015507:Drugs, Investigational; D011804:Quinolines; C087719:dofequidar